International Journal of Cancer · 2021 · 11 citations · 14 references
MedicineOncologyPharmacologyChemotherapyMetastasisMolecular OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyCancer BiomarkersCirculating Tumor Dna AnalysisNext-generation Sequencing In OncologyThromboembolism PreventionBiomarkers For Metastatic DiseaseCirculating Tumor Dna SequencingCirculating Tumor Dna TestingMetastatic Castration-resistant Prostate CancerPrognostic Marker EvaluationThromboembolism Risk PredictionVenous Thromboembolism BiomarkersVisceral Metastases
Cancer is a risk factor for venous thromboembolism (VTE). Plasma tumor DNA (ptDNA) is an independent predictor of outcome in metastatic castration-resistant prostate cancer (mCRPC). We aimed to investigate the association between ptDNA and VTE in mCRPC. This prospective biomarker study included 180 mCRPC patients treated with abiraterone and enzalutamide from April 2013 to December 2018. We excluded patients with a previous VTE history and/or ongoing anticoagulation therapy. Targeted next-generation sequencing was performed to determine ptDNA fraction from pretreatment plasma samples. VTE risk based on survival analysis was performed using cumulative incidence function and estimating sub-distributional hazard ratio (SHR). At a median follow-up of 58 months (range 0.5-111.0), we observed 21 patients who experienced VTE with a cumulative incidence at 12 months of 17.1% (95% confidence interval [CI] 10.3-23.9). Elevated ptDNA, visceral metastasis, prior chemotherapy and lactate dehydrogenase (LDH) were significantly associated with higher VTE incidence compared to patients with no thrombosis (12-month estimate, 18.6% vs 3.5%, P = .0003; 44.4% vs 14.8%, P = .015; 24.7% vs 4.5%, P = .006; and 30.0% vs 13.5%, P = .05, respectively). In the multivariate analysis including ptDNA level, visceral metastases, number of lesions and serum LDH, high ptDNA fraction was the only independent factor associated with the risk of thrombosis (HR 5.78, 95% CI 1.63-20.44, P = .006). These results first suggest that baseline ptDNA fraction in mCRPC patients treated with abiraterone or enzalutamide may be associated with increased VTE risk. These patients may be followed-up more closely for the VTE risk, and the need for a primary thromboprophylaxis should be taken into account in mCRPC with elevated ptDNA.
14
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana, Nicole M. Kuderer, Eva Culakova et al. · Blood · 2008 · 2.2K citations · Full text
Medicine, Hematology, Oncology +14